AUA 2017: AUA Guidelines 2017 – localized, high risk prostate cancer

Boston, MA (UroToday.com) Dr. Taplin spoke on the 2017 AUA guidelines for high-risk prostate cancer. The panel defined high-risk prostate cancer has Gleason grade group 4-5 (former Gleason sum 8-0), or PSA> 20, and stage T1-2. Further, the panel did not stratify patients into high risk and very high risk like the NCCN has done.

The recommendation statements are as follows:

  • All patients should have cross sectional imaging (CT scan or MRI) and bone scan
  • The standard therapy is radical prostatectomy OR radiation therapy with androgen deprivation therapy
  • Watchful waiting should only be considered in asymptomatic men with short life expectancies
  • Primary ADT should only be offered in symptomatic men with short life expectancy
  • Active surveillance is not recommended
  • Focal therapies including HIFU and cryoablation are not recommended
  • Clinicians should consider referral to genetic counseling for patients and their families with the combination of high-risk localized prostate cancer and a strong family history of specific cancers (breast, ovarian, pancreas, GI tumors, lymphoma)
  • Future directions include randomized trials to inform the proper role of focal ablative technology, new imaging modalities, and digital tools to facilitate shared decision-making


A complete summary of the new AUA localized prostate cancer guidelines can be found: http://www.auanet.org/guidelines/clinically-localized-prostate-cancer-new-(aua/astro/suo-guideline-2017)

Presented By: Mary Taplin, MD, Dana Farber Cancer Institute, Boston, MA

Written By: Benjamin T. Ristau, MD, Fox Chase Cancer Center, Philadelphia, PA

at the 2017 AUA Annual Meeting - May 12 - 16, 2017 – Boston, Massachusetts, USA
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe